Advertisement

Rare Tumors and Benign Diseases

  • Ugur Selek
  • Ugur Selek
  • Murat Beyzadeoglu
  • Gokhan Ozyigit
Chapter

Abstract

This book, arranged in an MCQ format complemented by oral exam questions, is designed to meet the needs of a wide range of examinees. Essential aspects of radiation physics, radiobiology, and clinical radiation oncology are well covered. Tumors at different sites are addressed in a series of individual chapters, and further chapters are devoted to lymphomas and total body irradiation, pediatric tumors, and rare tumors and benign diseases. The answer keys provide clear explanations for both the correct answers and incorrect statements.

Keywords

Androgen Deprivation Therapy Heterotopic Ossification Trigeminal Neuralgia Internal Auditory Canal Cavernous Malformation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL et al (2008) Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 115(2):398–409PubMedCrossRefGoogle Scholar
  2. 2.
    Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM (1993) Randomized double-blind trial of prednisone versus radiotherapy in Graves’ ophthalmopathy. Lancet 342(8877):949–954PubMedCrossRefGoogle Scholar
  3. 3.
    Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L et al (2004) A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab 89(1):15–20PubMedCrossRefGoogle Scholar
  4. 4.
    Wakelkamp IM, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank LE et al (2004) Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology 111(8):1557–1562PubMedCrossRefGoogle Scholar
  5. 5.
    Chole R, Patil R, Degwekar SS, Bhowate RR (2007) Drug treatment of trigeminal neuralgia: a systematic review of the literature. J Oral Maxillofac Surg 65(1):40–45PubMedCrossRefGoogle Scholar
  6. 6.
    Spatz AL, Zakrzewska JM, Kay EJ (2007) Decision analysis of medical and surgical treatments for trigeminal neuralgia: how patient evaluations of benefits and risks affect the utility of treatment decisions. Pain 131(3):302–310PubMedCrossRefGoogle Scholar
  7. 7.
    Brisman R (2007) Microvascular decompression vs. gamma knife radiosurgery for typical trigeminal neuralgia: preliminary findings. Stereotact Funct Neurosurg 85(2–3):94–98PubMedCrossRefGoogle Scholar
  8. 8.
    Cheng JS, Sanchez-Mejia RO, Limbo M, Ward MM, Barbaro NM (2005) Management of medically refractory trigeminal neuralgia in patients with multiple sclerosis. Neurosurg Focus 18(5):e13PubMedCrossRefGoogle Scholar
  9. 9.
    Spetzler RF, Martin NA (1986) A proposed grading system for arteriovenous malformations. J Neurosurg 65(4):476–483PubMedCrossRefGoogle Scholar
  10. 10.
    Brown RD Jr (2000) Simple risk predictions for arteriovenous malformation hemorrhage. Neurosurgery 46(4):1024PubMedGoogle Scholar
  11. 11.
    Kondziolka D, McLaughlin MR, Kestle JR (1995) Simple risk predictions for arteriovenous malformation hemorrhage. Neurosurgery 37(5):851–855PubMedCrossRefGoogle Scholar
  12. 12.
    Maruyama K, Kawahara N, Shin M, Tago M, Kishimoto J, Kurita H et al (2005) The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations. N Engl J Med 352(2):146–153PubMedCrossRefGoogle Scholar
  13. 13.
    Pollock BE, Meyer FB (2004) Radiosurgery for arteriovenous malformations. J Neurosurg 101(3):390–392; discussion 2PubMedCrossRefGoogle Scholar
  14. 14.
    Flickinger JC, Pollock BE, Kondziolka D, Lunsford LD (1996) A dose–response analysis of arteriovenous malformation obliteration after radiosurgery. Int J Radiat Oncol Biol Phys 36(4):873–879PubMedCrossRefGoogle Scholar
  15. 15.
    Karlsson B, Lindquist C, Steiner L (1997) Prediction of obliteration after gamma knife surgery for cerebral arteriovenous malformations. Neurosurgery 40(3):425–430; discussion 430–431PubMedGoogle Scholar
  16. 16.
    Hartmann A, Pile-Spellman J, Stapf C, Sciacca RR, Faulstich A, Mohr JP et al (2002) Risk of endovascular treatment of brain arteriovenous malformations. Stroke 33(7):1816–1820PubMedCrossRefGoogle Scholar
  17. 17.
    Starke RM, Komotar RJ, Otten ML, Hahn DK, Fischer LE, Hwang BY et al (2009) Adjuvant embolization with N-butyl cyanoacrylate in the treatment of cerebral arteriovenous malformations: outcomes, complications, and predictors of neurologic deficits. Stroke 40(8):2783–2790PubMedCrossRefGoogle Scholar
  18. 18.
    Ogilvy CS, Stieg PE, Awad I, Brown RD Jr, Kondziolka D, Rosenwasser R et al (2001) AHA Scientific Statement: recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Stroke 32(6):1458–1471PubMedCrossRefGoogle Scholar
  19. 19.
    Ogilvy CS, Stieg PE, Awad I, Brown RD Jr, Kondziolka D, Rosenwasser R et al (2001) Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Circulation 103(21):2644–2657PubMedGoogle Scholar
  20. 20.
    Pakos EE, Ioannidis JP (2004) Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 60(3):888–895PubMedCrossRefGoogle Scholar
  21. 21.
    Seegenschmiedt MH, Makoski HB, Micke O (2001) Radiation prophylaxis for heterotopic ossification about the hip joint – a multicenter study. Int J Radiat Oncol Biol Phys 51(3):756–765PubMedCrossRefGoogle Scholar
  22. 22.
    Kal HB, Veen RE (2005) Biologically effective doses of postoperative radiotherapy in the prevention of keloids. Dose-effect relationship. Strahlenther Onkol 181(11):717–723PubMedCrossRefGoogle Scholar
  23. 23.
    Flickinger JC (2011) A radiobiological analysis of multicenter data for postoperative keloid radiotherapy. Int J Radiat Oncol Biol Phys 79(4):1164–1170PubMedCrossRefGoogle Scholar
  24. 24.
    Di Lorenzo G, Autorino R, Perdona S, De Placido S (2005) Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol 6(12):972–979PubMedCrossRefGoogle Scholar
  25. 25.
    Di Lorenzo G, Perdona S, De Placido S, D’Armiento M, Gallo A, Damiano R et al (2005) Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 174(6):2197–2203PubMedCrossRefGoogle Scholar
  26. 26.
    Perdona S, Autorino R, De Placido S, D’Armiento M, Gallo A, Damiano R et al (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6(5):295–300PubMedCrossRefGoogle Scholar
  27. 27.
    El-Sakka AI, Yassin AA (2008) Conservative treatment for Peyronie’s disease: an update. Expert Opin Pharmacother 9(1):53–63PubMedCrossRefGoogle Scholar
  28. 28.
    Incrocci L, Hop WC, Seegenschmiedt HM (2008) Radiotherapy for Peyronie’s disease: a European survey. Acta Oncol 47(6):1110–1112PubMedCrossRefGoogle Scholar
  29. 29.
    Incrocci L, Hop WC, Slob AK (2000) Current sexual functioning in 106 patients with Peyronie’s disease treated with radiotherapy 9 years earlier. Urology 56(6):1030–1034PubMedCrossRefGoogle Scholar
  30. 30.
    Incrocci L, Wijnmaalen A, Slob AK, Hop WC, Levendag PC (2000) Low-dose radiotherapy in 179 patients with Peyronie’s disease: treatment outcome and current sexual functioning. Int J Radiat Oncol Biol Phys 47(5):1353–1356PubMedCrossRefGoogle Scholar
  31. 31.
    Niewald M, Wenzlawowicz KV, Fleckenstein J, Wisser L, Derouet H, Rube C (2006) Results of radiotherapy for Peyronie’s disease. Int J Radiat Oncol Biol Phys 64(1):258–262PubMedCrossRefGoogle Scholar
  32. 32.
    Seegenschmiedt MH, Katalinic A, Makoski H, Haase W, Gademann G, Hassenstein E (2000) Radiation therapy for benign diseases: patterns of care study in Germany. Int J Radiat Oncol Biol Phys 47(1):195–202PubMedCrossRefGoogle Scholar
  33. 33.
    Muecke R, Micke O, Reichl B, Heyder R, Prott FJ, Seegenschmiedt MH et al (2007) Demographic, clinical and treatment related predictors for event-free probability following low-dose radiotherapy for painful heel spurs – a retrospective multicenter study of 502 patients. Acta Oncol 46(2):239–246PubMedCrossRefGoogle Scholar
  34. 34.
    Heyd R, Tselis N, Ackermann H, Roddiger SJ, Zamboglou N (2007) Radiation therapy for painful heel spurs: results of a prospective randomized study. Strahlenther Onkol 183(1):3–9PubMedCrossRefGoogle Scholar
  35. 35.
    Surenkok S, Dirican B, Beyzadeoglu M, Oysul K (2006) Heel spur radiotherapy and radiation carcinogenesis risk estimation. Radiat Med 24(8):573–576PubMedCrossRefGoogle Scholar
  36. 36.
    Kollert M, Minovi A, Mangold R, Hendus J, Draf W, Bockmuhl U (2006) Paraganglioma of the head and neck–tumor control, functional results and quality of life. Laryngorhinootologie 85(9):649–656PubMedCrossRefGoogle Scholar
  37. 37.
    Semaan MT, Megerian CA (2008) Current assessment and management of glomus tumors. Curr Opin Otolaryngol Head Neck Surg 16(5):420–426PubMedCrossRefGoogle Scholar
  38. 38.
    Martin JJ, Kondziolka D, Flickinger JC, Mathieu D, Niranjan A, Lunsford LD (2007) Cranial nerve preservation and outcomes after stereotactic radiosurgery for jugular foramen schwannomas. Neurosurgery 61(1):76–81; discussion 81PubMedCrossRefGoogle Scholar
  39. 39.
    Lim M, Bower R, Nangiana JS, Adler JR, Chang SD (2007) Radiosurgery for glomus jugulare tumors. Technol Cancer Res Treat 6(5):419–423PubMedGoogle Scholar
  40. 40.
    Li G, Chang S, Adler JR Jr, Lim M (2007) Irradiation of glomus jugulare tumors: a historical perspective. Neurosurg Focus 23(6):E13PubMedCrossRefGoogle Scholar
  41. 41.
    Krych AJ, Foote RL, Brown PD, Garces YI, Link MJ (2006) Long-term results of irradiation for paraganglioma. Int J Radiat Oncol Biol Phys 65(4):1063–1066PubMedCrossRefGoogle Scholar
  42. 42.
    Acciarri N, Galassi E, Giulioni M, Pozzati E, Grasso V, Palandri G et al (2009) Cavernous malformations of the central nervous system in the pediatric age group. Pediatr Neurosurg 45(2):81–104PubMedCrossRefGoogle Scholar
  43. 43.
    Hasegawa T, McInerney J, Kondziolka D, Lee JY, Flickinger JC, Lunsford LD (2002) Long-term results after stereotactic radiosurgery for patients with cavernous malformations. Neurosurgery 50(6):1190–1197; discussion 7–8PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Ugur Selek
    • 1
  • Ugur Selek
    • 2
  • Murat Beyzadeoglu
    • 3
  • Gokhan Ozyigit
    • 4
  1. 1.MD Anderson Cancer CenterUniversity of TexasIstanbulTurkey
  2. 2.MD Anderson Radiation OncologyCenter at American Hospital-Istanbul NisantasiIstanbulTurkey
  3. 3.Department of RadiationGulhane Military Medical SchoolEtlik, AnkaraTurkey
  4. 4.Department of Radiation Oncology Faculty of MedicineHacettepe UniversitySihhiye, AnkaraTurkey

Personalised recommendations